Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

enVVeno Medical (NVNO) Research & Development (2017 - 2020)

enVVeno Medical has reported Research & Development over the past 4 years, most recently at $2.3 million for Q4 2020.

  • For Q4 2020, Research & Development rose 189.06% year-over-year to $2.3 million; the TTM value through Dec 2020 reached $4.3 million, up 92.75%, while the annual FY2025 figure was $10.0 million, 18.52% down from the prior year.
  • Research & Development for Q4 2020 was $2.3 million at enVVeno Medical, up from $758198.0 in the prior quarter.
  • Over five years, Research & Development peaked at $2.3 million in Q4 2020 and troughed at $43069.0 in Q3 2017.
  • A 4-year average of $551612.9 and a median of $424596.0 in 2018 define the central range for Research & Development.
  • On a YoY basis, Research & Development climbed as much as 885.85% in 2018 and fell as far as 16.0% in 2018.
  • Year by year, Research & Development stood at $349088.0 in 2017, then fell by 16.0% to $293241.0 in 2018, then soared by 168.66% to $787827.0 in 2019, then soared by 189.06% to $2.3 million in 2020.
  • Business Quant data shows Research & Development for NVNO at $2.3 million in Q4 2020, $758198.0 in Q3 2020, and $706173.0 in Q2 2020.